Hedeker Wealth LLC Buys 108 Shares of Zoetis Inc. (NYSE:ZTS)

Hedeker Wealth LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,622 shares of the company’s stock after purchasing an additional 108 shares during the quarter. Hedeker Wealth LLC’s holdings in Zoetis were worth $1,242,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in shares of Zoetis by 0.5% during the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after buying an additional 95,856 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock worth $2,030,813,000 after buying an additional 185,364 shares during the last quarter. Mizuho Securities USA LLC lifted its holdings in shares of Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after buying an additional 4,829,815 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Zoetis by 5.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after buying an additional 194,542 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $174.07 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock has a fifty day moving average price of $169.39 and a two-hundred day moving average price of $179.32. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The firm has a market capitalization of $78.54 billion, a P/E ratio of 32.72, a P/E/G ratio of 2.72 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the company posted $1.36 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.15%. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio is currently 37.59%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Morgan Stanley cut their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.